Literature DB >> 16614244

Competition within the early B-cell compartment conditions B-cell reconstitution after hematopoietic stem cell transplantation in nonirradiated recipients.

Allen Liu1, Christian A J Vosshenrich, Chantal Lagresle-Peyrou, Michele Malassis-Seris, Christophe Hue, Alain Fischer, James P Di Santo, Marina Cavazzana-Calvo.   

Abstract

Severe combined immunodeficiency (SCID) is characterized by a complete block in T-lymphocyte differentiation. Most SCID also affects B-cell development or function, although a normal pool of pro-B cells is detectable. Treatment of SCID consists of allogeneic hematopoietic stem cell transplantation (HSCT), but in the absence of a myeloablative conditioning regimen, only T cells, and in some cases, natural killer (NK) cells, are of donor origin, while all other leukocytes subsets are of host origin. We hypothesized that donor B-cell development success could be conditioned by the competitive ability of recipient B-cell precursors in the bone marrow. We therefore compared the outcome of unconditioned HSCT in mice that differed with respect to their pro-B-cell compartments. B-cell reconstitution was limited in recipient mice containing a normal pro-B-cell pool, whereas immature and mature B-cell numbers reached wild-type levels in mice with compromised early B-cell precursors. Interestingly, host NK cells did not modify the outcome of unconditioned HSCT as long as the early B-cell compartment was compromised. These observations suggest that recipient B-cell precursors condition the reconstitution of the donor B-cell pool and, if extrapolative to humans, suggest that conditioning regimens targeting host pro-B cells may help improve B-cell reconstitution after allogeneic HSCT.

Entities:  

Mesh:

Year:  2006        PMID: 16614244     DOI: 10.1182/blood-2006-01-0061

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim sustains B lymphopoiesis in the absence of IL-7.

Authors:  Nicholas D Huntington; Verena Labi; Ana Cumano; Paulo Vieira; Andreas Strasser; Andreas Villunger; James P Di Santo; Nuno L Alves
Journal:  Int Immunol       Date:  2009-05-19       Impact factor: 4.823

2.  Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer.

Authors:  Gustavo Mostoslavsky; Attila J Fabian; Sean Rooney; Frederick W Alt; Richard C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-24       Impact factor: 11.205

3.  Hematopoietic cell transplantation for treatment of primary immune deficiencies.

Authors:  Lauri Burroughs; Ann Woolfrey
Journal:  Cell Ther Transplant       Date:  2010-08-31

4.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

Review 5.  The biology of allogeneic hematopoietic cell resistance.

Authors:  Judith A Shizuru; Deepta Bhattacharya; Marina Cavazzana-Calvo
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-12       Impact factor: 5.742

6.  Longitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency.

Authors:  Alessia Scarselli; Silvia Di Cesare; Claudia Capponi; Simona Cascioli; Maria L Romiti; Gigliola Di Matteo; Alessandra Simonetti; Paolo Palma; Andrea Finocchi; Barbarella Lucarelli; Rita M Pinto; Ippolita Rana; Giuseppe Palumbo; Maurizio Caniglia; Paolo Rossi; Rita Carsetti; Caterina Cancrini; Alessandro Aiuti
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

7.  Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation.

Authors:  Laura Garcia-Perez; Lieke van Roon; Marco W Schilham; Arjan C Lankester; Karin Pike-Overzet; Frank J T Staal
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

Review 8.  Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency.

Authors:  Anna Villa; Valentina Capo; Maria Carmina Castiello
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

Review 9.  Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.

Authors:  Elena Blanco; Natalia Izotova; Claire Booth; Adrian James Thrasher
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.